FINWIRES · TerminalLIVE
FINWIRES

Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says

By

Illumina's (ILMN) mid-teens clinical growth appears sustainable over the next one to two years, driven largely by oncology testing and screening applications, as the company sees building clinical momentum and fading competitive concerns, RBC said in a Thursday note.

With clinical markets now comprising over 50% of the company's sales, growth has accelerated to 20% in each of the past two quarters, supported by robust growth forecasts for Illumina's oncology customers, according to the note.

Illumina sees fading competitive concerns with Roche's Axelios 1 sequencing update seeing mixed response, RBC said, adding that it did not see any updates at Roche's investor event earlier this week to change the narrative.

Additionally, RBC said that the weakness Illumina is seeing in academic demand is an industry-wide problem and that several new product launches should enable demand to at least flatten by next year, which will be enough to meet or exceed Wall Street forecasts.

RBC has an outperform rating on the company, with a $170 price target.

Price: $139.93, Change: $-3.31, Percent Change: -2.31%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC